| Alzamend Neuro is a specialty pharmaceutical company engaged in the development and commercialization of patented intellectual property to prevent, treat and cure Alzheimer's disease ("Alzheimer's" or "AD"). Co. has licensed an immunotherapy vaccine peptide that works both as a treatment and vaccine against Alzheimer's and an ionic cocrystal of lithium to mitigate extreme agitation and forestall other deterioration as displayed by patients with up to moderate AD and possibly other neurodegenerative diseases. Co. devotes substantially all its efforts towards research and development of its Technology and raising capital. We show 4 historical shares outstanding datapoints in our ALZN shares outstanding history coverage, used to compute ALZN market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALZN market cap history over the course of time is important for investors
interested in comparing ALZN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALZN versus a peer is one thing; comparing
ALZN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALZN can fluctuate over the course of history.
With this page we aim to empower investors researching ALZN by allowing them to research the ALZN market cap history.